Vor Biopharma

Robert Ang, M.D., CEO

Oct. 13 | 5:15pm | AVROBIO Ballroom

Cambridge, MA

(NASDAQ: VOR)

In-person Presentation

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells.

www.vorbio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions